Search the Newsreel

Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease

Sanofi's oral TREM2 agonist, SAR448851, is progressing to a Phase 2 clinical trial named TREMHANCE for early Alzheimer's disease. The trial will evaluate the drug's efficacy and safety, with the primary endpoint being the change in plasma p-tau217 at week 48, aiming to shift …

Aqemia Expands Sanofi AI Drug Discovery Deal

Aqemia and Sanofi have expanded their multi-year drug discovery collaboration, with Aqemia announcing a new therapeutic target nomination. This expansion makes Aqemia eligible for up to $140 million in aggregate payments. The partnership utilizes Aqemia's physics-based generative AI platform, Qemi, to design molecules for …

Aqemia and Sanofi Expand Their Research Collaboration

Aqemia and Sanofi have expanded their multi-year research collaboration, initially announced in December 2023. The expansion involves the nomination of a new therapeutic target and an additional milestone payment to Aqemia, bringing the potential total payments to $140 million. This partnership leverages Aqemia's generative …

FDA clears Sarclisa Escena on-body injector for Sanofi (NASDAQ: SNY)

The US FDA has approved Sanofi's subcutaneous Sarclisa Escena (isatuximab-irfc) for multiple myeloma, making it the first anticancer treatment to be administered via an on-body injector or manual subcutaneous injection. This approval expands Sarclisa's use across all existing IV indications. The pivotal IRAKLIA phase …

Sanofi Doesn’t Want AI to Automate Work. It Wants to Reinvent It.

Sanofi is aiming to become the first biopharma company powered by AI at scale, applying AI throughout the entire medicine development journey from discovery to commercialization. Emmanuel Frenehard, Sanofi's Chief Digital Officer, emphasizes that AI should be used to reinvent business processes rather than …

Sanofi joins the mRNA vaccine patent wars

Sanofi has initiated lawsuits against Pfizer and Moderna, alleging infringement of its patents related to the delivery of messenger RNA using lipid nanoparticles in their COVID-19 and RSV vaccines. Acquired through the 2021 Translate Bio purchase, these patents represent Sanofi's strategy to gain value …

Sanofi, Lilly back AdvanCell's $315M radiopharmaceutical push

The article reports that Sanofi and Lilly are investing in AdvanCell's $315 million radiopharmaceutical initiative. This significant backing from major pharmaceutical companies highlights growing interest and investment in radiopharmaceutical development. The collaboration aims to advance AdvanCell's efforts in this specialized area of medicine.

Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas

Sanofi has initiated new patent infringement lawsuits against Pfizer and Moderna, targeting the lipid nanoparticle (LNP) technology used in their COVID-19 vaccines and Moderna's RSV vaccine. Sanofi claims the LNP tech, developed by its acquired Translate Bio, infringes on its patents related to mRNA …

Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals

Strong Buy Rating on Sanofi (SNY) Following Positive Study Resul

SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals

Sanofi Tops Q1 Earnings Estimates as Dupixent & New Drugs Drive Growth

Earnings call transcript: Sanofi’s Q1 2026 earnings beat forecasts, stock rises

Sanofi (SNY) Q1 Earnings Exceed Expectations with Strong Sales G

Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening

Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite

Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026

Sanofi ADR earnings beat by $0.69, revenue fell short of estimates

SANOFI-ADR (NASDAQ:SNY) – A Strong Dividend Stock with Solid Fundamentals